Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.60 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 3/20 | 0.51 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19859011 | 0.90 | ALDH1A1 (0.57) | ALDH1A1LMNACASP3SENP8SENP6 | |
| SCHEMBL19859013 | 0.90 | ALDH1A1 (0.57) | ALDH1A1LMNACASP3SENP8SENP6 | |
| SCHEMBL19859012 | 0.90 | ALDH1A1 (0.57) | ALDH1A1LMNACASP3SENP8SENP6 | |
| SCHEMBL1977190 | 0.87 | ALDH1A1 (0.70) | ALDH1A1LMNACASP3SENP8SENP6 | |
| SCHEMBL15717703 | 0.86 | ALDH1A1 (0.53) | ALDH1A1LMNACASP3SENP8SENP6 | |
| SCHEMBL15717433 | 0.86 | ALDH1A1 (0.53) | ALDH1A1LMNACASP3SENP8SENP6 | |
| SCHEMBL15717432 | 0.86 | ALDH1A1 (0.53) | ALDH1A1LMNACASP3SENP8SENP6 | |
| SCHEMBL197827 | 0.85 | PARP10 (0.50) | ALDH1A1LMNACASP3SENP8SENP6 | |
| SCHEMBL3012096 | 0.85 | PARP10 (0.73) | ALDH1A1SENP8SENP6EPHX2PARP10 | |
| SCHEMBL1028676 | 0.84 | EPHX2 (0.68) | ALDH1A1LMNACASP3SENP8SENP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2012500192-A | — | — | 2012-01-05 | — | — | JP | claimed |
| EP-2326642-A2 | SALT OF, AND PROCESSES FOR THE PREPARATION OF, 1-ISOPROPYL-4-{[4-(TETRAHYDRO-2H-PYRAN- 4-YLOXY)PHENYL]CARBONYL}HEXAHYDRO-1H-1,4-DIAZEPINE | Glaxo Group Limited (GB) | 2011-06-01 | — | — | EP | claimed |
| US-20100204242-A1 | Piperazine Derivative Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2010-08-12 | — | — | US | claimed |
| EP-2195307-A1 | PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | Glaxo Group Limited (GB) | 2010-06-16 | — | — | EP | claimed |
| WO-2010018231-A2 | SALT OF, AND PROCESSES FOR THE PREPARATION OF, 1-ISOPROPYL-4-{[4-(TETRAHYDRO-2H-PYRAN- 4-YLOXY)PHENYL]CARBONYL}HEXAHYDRO-1H-1,4-DIAZEPINE | GLAXO GROUP LIMITED (GB) | 2010-02-18 | — | — | WO | claimed |
| US-20090170869-A1 | PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | US | claimed |
| WO-2009030716-A1 | PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2009-03-12 | — | — | WO | claimed |
| US-20260027106-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2026-01-29 | — | — | US | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-12 | — | — | US | disclosed |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| WO-2009030716-A1 | PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009030716-A1 | PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2009-03-12 | — | — | WO | disclosed |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080045505-A1 | 1-Benzoyl Substituted Diazepine Derivatives As Selective Histamine H3 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| EP-1675838-A1 | 1-BENZOYL SUBSTITUTED DIAZEPINE DERIVATIVES AS SELECTIVE HISTAMINE H3 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005040144-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027106-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | ALDH1A1 3490/4885LMNA 1826/4885CASP3 4616/4885 |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | ALDH1A1 621/4885LMNA 2153/4885CASP3 2200/4885 |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | S1PR1, S1PR2, S1PR4 | ALDH1A1 708/4885LMNA 3705/4885CASP3 2755/4885 |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | ALDH1A1 621/4885LMNA 2153/4885CASP3 2200/4885 |
| US-20090170869-A1 | PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | ALDH1A1 4338/4885LMNA 4432/4885CASP3 4718/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | ALDH1A1 621/4885LMNA 2153/4885CASP3 2200/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | ALDH1A1 4172/4885LMNA 3454/4885CASP3 4375/4885 |
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | ALDH1A1 3818/4885LMNA 2140/4885CASP3 3116/4885 |
| US-20100204242-A1 | Piperazine Derivative Having Affinity for the Histamine H3 Receptor | HRH3, HRH4, HRH1 | ALDH1A1 4338/4885LMNA 4432/4885CASP3 4718/4885 |
| US-20080045505-A1 | 1-Benzoyl Substituted Diazepine Derivatives As Selective Histamine H3 Receptor Agonists | HRH3, HRH4, HRH1 | ALDH1A1 1006/4885LMNA 4523/4885CASP3 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.